Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

References

• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11–20. PubMed PMID: 28930295.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388–1402. PubMed PMID: 27062661. DOI:10.1016/j.jhep.2015.11.004.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metab Clin Exp. 2017 Jun;71:17–32. PubMed PMID: 28521870.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015 Jun 14;21(22):6820–6834. PubMed PMID: 26078558; PubMed Central PMCID: PMC4462722.
   PubMed Web of Science ®Google Scholar
• Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015 Jul 7;21(25):7860–7868. PubMed PMID: 26167086; PubMed Central PMCID: PMC4491973.
   PubMed Web of Science ®Google Scholar
• Singh S, Khera R, Allen AM, et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015 Nov;62(5):1417–1432. PubMed PMID: 26189925.
   PubMed Web of Science ®Google Scholar
• Lombardi R, Onali S, Thorburn D, et al. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev. 2017 Mar;30(3):CD011640. PubMed PMID: 28358980. DOI:10.1002/14651858.CD011640.pub2.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):196–205. PubMed PMID: 26907882. DOI:10.1038/nrgastro.2016.3.
   PubMed Web of Science ®Google Scholar
• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama. 2015 Jun 9;313(22):2263–2273. PubMed PMID: 26057287. DOI:10.1001/jama.2015.5370.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clinic Gastroenterol Hepatol: Off Clinic Pract J Am Gastroenterol Assoc. 2015 Apr;13(4):643–54 e1–9; quiz e39–40. PubMed PMID: 24768810; PubMed Central PMCID: PMC4208976.
   Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017 May;65(5):1557–1565. PubMed PMID: 28130788; PubMed Central PMCID: PMC5397356. DOI:10.1002/hep.29085.
   PubMed Web of Science ®Google Scholar
• Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017 Jan;66(1):180–190. PubMed PMID: 27646933. DOI:10.1136/gutjnl-2016-312431.
   PubMed Web of Science ®Google Scholar
• Baba M, Takashima K, Miyake H, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005 Nov;49(11):4584–4591. PubMed PMID: 16251299; PubMed Central PMCID: PMC1280155.
   PubMed Web of Science ®Google Scholar
• Lalezari J, Gathe J, Brinson C, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 01;57(2):118–125. PubMed PMID: 21317794.
   PubMed Web of Science ®Google Scholar
• Lefebvre E, Gottwald M, Lasseter K, et al. Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139–148. PubMed PMID: 27169903; PubMed Central PMCID: PMC5351328.
   PubMed Web of Science ®Google Scholar
• Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014 Sep;147(3):577–594 e1. PubMed PMID: 25066692. DOI:10.1053/j.gastro.2014.06.043.
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets. 2011 Dec;10(6):509–536. PubMed PMID: 22150762.
   PubMedGoogle Scholar
• Krenkel O, Tacke F. Macrophages in nonalcoholic fatty liver disease: a role model of pathogenic immunometabolism. Semin Liver Dis. 2017 Aug;37(3):189–197. PubMed PMID: 28847030. DOI:10.1055/s-0037-1604480.
   PubMed Web of Science ®Google Scholar
• Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017 May;17(5):306–321. PubMed PMID: 28317925. DOI:10.1038/nri.2017.11.
   PubMed Web of Science ®Google Scholar
• Devisscher L, Scott CL, Lefere S, et al. Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. Cell Immunol. 2017 Oct 16. PubMed PMID: 29111158. DOI:10.1016/j.cellimm.2017.10.006.
   PubMed Web of Science ®Google Scholar
• Dambach DM, Watson LM, Gray KR, et al. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology. 2002 May;35(5):1093–1103. PubMed PMID: 11981759.
   PubMed Web of Science ®Google Scholar
• Seki E, de Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009 Jul;50(1):185–197. PubMed PMID: 19441102; PubMed Central PMCID: PMC2705470.
   PubMed Web of Science ®Google Scholar
• Seki E, de Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007 Nov;13(11):1324–1332. PubMed PMID: 17952090.
   PubMed Web of Science ®Google Scholar
• Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009 Jul;50(1):261–274. PubMed PMID: 19554540. DOI:10.1002/hep.22950.
   PubMed Web of Science ®Google Scholar
• Holt MP, Cheng L, Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol. 2008 Dec;84(6):1410–1421. PubMed PMID: 18713872; PubMed Central PMCID: PMC2614594. DOI:10.1189/jlb.0308173.
   PubMed Web of Science ®Google Scholar
• Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006 Jun;116(6):1494–1505. PubMed PMID: 16691291; PubMed Central PMCID: PMC1459069.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006 Jan;116(1):115–124. PubMed PMID: 16341265; PubMed Central PMCID: PMC1307559.
   PubMed Web of Science ®Google Scholar
• Obstfeld AE, Sugaru E, Thearle M, et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010 Apr;59(4):916–925. PubMed PMID: 20103702; PubMed Central PMCID: PMC2844839.
   PubMed Web of Science ®Google Scholar
• Miura K, Yang L, Van Rooijen N, et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointestinal Liver Physiol. 2012 Jun 01;302(11):G1310–21. PubMed PMID: 22442158; PubMed Central PMCID: PMC3378163.
   PubMed Web of Science ®Google Scholar
• Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2012 Mar;61(3):416–426. PubMed PMID: 21813474.
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Seidler S, Nattermann J, et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One. 2010 Jun 10;5(6):e11049. PubMed PMID: 20548789; PubMed Central PMCID: PMC2883575.
   PubMed Web of Science ®Google Scholar
• Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006 Jun;44(6):1167–1174. PubMed PMID: 16618517.
   PubMed Web of Science ®Google Scholar
• du Plessis J, van Pelt J, Korf H, et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology. 2015 Sep;149(3):635–48 e14. PubMed PMID: 26028579.
   PubMed Web of Science ®Google Scholar
• Krenkel O, Puengel T, Govaere O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2017 Sep 21; in press. PubMed PMID: 28940700. DOI:10.1002/hep.29544.
   PubMedGoogle Scholar
• Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017 Jun;66(6):1300–1312. PubMed PMID: 28267621. DOI:10.1016/j.jhep.2017.02.026.
   PubMed Web of Science ®Google Scholar
• Kitade H, Sawamoto K, Nagashimada M, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes. 2012 Jul;61(7):1680–1690. PubMed PMID: 22474027; PubMed Central PMCID: PMC3379680.
   PubMed Web of Science ®Google Scholar
• Seki E, de Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009 Jul;119(7):1858–1870. PubMed PMID: 19603542; PubMed Central PMCID: PMC2701864.
   PubMed Web of Science ®Google Scholar
• Berres ML, Koenen RR, Rueland A, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010 Nov;120(11):4129–4140. PubMed PMID: 20978355; PubMed Central PMCID: PMC2964968.
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointestinal Liver Physiol. 2003 Nov;285(5):G949–58. PubMed PMID: 12829440. DOI:10.1152/ajpgi.00215.2003.
   PubMed Web of Science ®Google Scholar
• Li BH, He FP, Yang X, et al. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl Res: J Lab Clin Med. 2017 Feb;180:103–117 e4. PubMed PMID: 27639593.
   Google Scholar
• Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11(6):e0158156. PubMed PMID: 27347680; PubMed Central PMCID: PMC4922569.
   PubMed Web of Science ®Google Scholar
• Puengel T, Krenkel O, Kohlhepp M, et al. Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLoS One. 2017;12(9):e0184694. PubMed PMID: 28910354; PubMed Central PMCID: PMC5598992. DOI:10.1371/journal.pone.0184694.
   PubMed Web of Science ®Google Scholar
• Mossanen JC, Krenkel O, Ergen C, et al. Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury. Hepatology. 2016 Nov;64(5):1667–1682. PubMed PMID: 27302828. DOI:10.1002/hep.28682.
   PubMed Web of Science ®Google Scholar
• Dal-Secco D, Wang J, Zeng Z, et al. A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. J Exp Med. 2015 Apr 06;212(4):447–456. PubMed PMID: 25800956; PubMed Central PMCID: PMC4387291.
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Pellicoro A, Vernon MA, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci USA. 2012 Nov 13;109(46):E3186–95. PubMed PMID: 23100531; PubMed Central PMCID: PMC3503234.
   PubMed Web of Science ®Google Scholar
• Baeck C, Wei X, Bartneck M, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology. 2014 Mar;59(3):1060–1072. PubMed PMID: 24481979.
   PubMed Web of Science ®Google Scholar
• Mulder P, van Den Hoek AM, Kleemann R. The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and non-alcoholic steatohepatitis. PLoS One. 2017;12(1):e0169740. PubMed PMID: 28076416; PubMed Central PMCID: PMC5226841. DOI:10.1371/journal.pone.0169740.
   PubMed Web of Science ®Google Scholar
• Tamura Y, Sugimoto M, Murayama T, et al. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb. 2010 Mar 31;17(3):219–228. PubMed PMID: 20179360
   PubMed Web of Science ®Google Scholar
• Ehling J, Bartneck M, Wei X, et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut. 2014 Dec;63(12):1960–1971. PubMed PMID: 24561613; PubMed Central PMCID: PMC4216733.
   PubMed Web of Science ®Google Scholar
• Thompson M, Saag M, DeJesus E, et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. Aids. 2016 Mar 27;30(6):869–878. PubMed PMID: 26636929; PubMed Central PMCID: PMC4794136.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015 Jul;63(1):237–264. PubMed PMID: 25911335. DOI:10.1016/j.jhep.2015.04.006.
   PubMed Web of Science ®Google Scholar
• Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016 Mar;47:356–365. PubMed PMID: 26944023. DOI:10.1016/j.cct.2016.02.012.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2017 Aug 17. PubMed PMID: 28833331. DOI:10.1002/hep.29477.
   Google Scholar
• Surewaard BG, Deniset JF, Zemp FJ, et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med. 2016 Jun 27;213(7):1141–1151. PubMed PMID: 27325887; PubMed Central PMCID: PMC4925027.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Surewaard BG, Wong CH, et al. CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne gram-positive bacteria. Cell Host Microbe. 2016 Jul 13;20(1):99–106. PubMed PMID: 27345697.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956–965. PubMed PMID: 25468160; PubMed Central PMCID: PMC4447192.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016 May;150(5):1147–1159 e5. PubMed PMID: 26874076.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016 Sep;65(3):589–600. PubMed PMID: 27212244.
   PubMed Web of Science ®Google Scholar
• Heymann F, Hammerich L, Storch D, et al. Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology. 2012 Mar;55:898–909. eng. DOI:10.1002/hep.24764
   PubMed Web of Science ®Google Scholar
• Karlmark KR, Zimmermann HW, Roderburg C, et al. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology. 2010 Nov;52(5):1769–1782. PubMed PMID: 21038415.
   PubMed Web of Science ®Google Scholar
• Zhang X, Han J, Man K, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016 Jan;64(1):160–170. PubMed PMID: 26394162.
   PubMed Web of Science ®Google Scholar
• Tomita K, Freeman BL, Bronk SF, et al. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Sci Rep. 2016;6:28786. PubMed PMID: 27349927; PubMed Central PMCID: PMC4923862. DOI:10.1038/srep28786.
   PubMed Web of Science ®Google Scholar
• Weiskirchen R, Tacke F. Liver fibrosis: from pathogenesis to novel therapies. Dig Dis. 2016;34(4):410–422. PubMed PMID: 27170396. DOI:10.1159/000444556.
   PubMed Web of Science ®Google Scholar
• Heymann F, Tacke F. Immunology in the liver–from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):88–110. PubMed PMID: 26758786. DOI:10.1038/nrgastro.2015.200.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015 May;61(5):1547–1554. PubMed PMID: 25125077.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015 Aug;149(2):389–397 e10. PubMed PMID: 25935633; PubMed Central PMCID: PMC4516664.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011 Sep 22;365(12):1118–1127. PubMed PMID: 21992124. DOI:10.1056/NEJMra1001683.
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology. 2016 Mar;63(3):827–838. PubMed PMID: 26599351.
   PubMed Web of Science ®Google Scholar
• Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clinic Gastroenterol Hepatol: Off Clinic Pract J Am Gastroenterol Assoc. 2016 Jan;14(1):124–131 e1. PubMed PMID: 26196445; PubMed Central PMCID: PMC4690789.
   PubMed Web of Science ®Google Scholar
• Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018 Feb;68(2):326–334. PubMed PMID: 29122695. DOI:10.1016/j.jhep.2017.10.006.
   PubMed Web of Science ®Google Scholar
• Ehling J, Tacke F. Role of chemokine pathways in hepatobiliary cancer. Cancer Lett. 2016;379(2):173–183.
   PubMed Web of Science ®Google Scholar
• Eggert T, Wolter K, Ji J, et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell. 2016 Oct 10;30(4):533–547. PubMed PMID: 27728804.
   PubMed Web of Science ®Google Scholar
• Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011 Nov 09;479(7374):547–551. PubMed PMID: 22080947.
   PubMed Web of Science ®Google Scholar
• Schneider C, Teufel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut. 2012 Dec;61(12):1733–1743. PubMed PMID: 22267597; PubMed Central PMCID: PMC4533880.
   PubMed Web of Science ®Google Scholar
• Li X, Yao W, Yuan Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017 Jan;66(1):157–167. PubMed PMID: 26452628.
   PubMed Web of Science ®Google Scholar